Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5 influenza vaccine-Sanofi-respiratory syncytial virus-influenza A(H5N1)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H5 influenza vaccine-Sanofi-respiratory syncytial virus-influenza A(H5N1) refers to a set of investigational mRNA-based vaccine candidates developed by Sanofi to target avian influenza A(H5N1) and respiratory syncytial virus (RSV). These candidates were evaluated in a Phase 1 clinical trial (NCT05430620) to assess the safety and immunogenicity of various formulations. The vaccines function by delivering mRNA encoding specific viral proteins—the hemagglutinin (H5) protein for the influenza component and a monovalent antigen (typically the fusion protein) for the RSV component—into host cells, which then produce the antigens to trigger an immune response. This program leverages Sanofi's mRNA platform, which was significantly expanded through the acquisition of Translate Bio, and aims to address both pandemic influenza preparedness and the prevention of RSV-related respiratory disease.
- Other names
- RSV and Flu H5 mRNA vaccinesSanofi mRNA H5N1 vaccineSanofi mRNA RSV vaccine
02
Targets
HA (Hemagglutinin)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on H5 influenza vaccine-Sanofi-respiratory syncytial virus-influenza A(H5N1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5 influenza vaccine-Sanofi-respiratory syncytial virus-influenza A(H5N1).